Skip to content

US · IOVA · BIOTECHNOLOGY

Iovance Biotherapeutics, Inc. (IOVA) intrinsic value and stock valuation

$6.90as of 2026-11-21 · Mkt cap 1.94B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Iovance Biotherapeutics, Inc. DCF and intrinsic value

InvestorsCraft values IOVA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IOVA’s statements →

Iovance Biotherapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Carlos, CA 94070 iovance.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$263.5M
20112025
Net income
-$-390.98M
20112025
Free cash flow
-$-336.24M
20112025
Total equity
$698.6M+1.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$263.5M$164.1M$1.19M$0.00$0.00
Operating income-$-403.36M-$-395.28M-$-460.56M-$-398.88M-$-342.7M
Net income-$-390.98M-$-372.18M-$-444.04M-$-395.89M-$-342.25M
EPSd-$-1.09M-$-1.28M-$-1.89M-$-2.49M-$-2.23M
Operating cash flow-$-302.41M-$-352.98M-$-361.82M-$-292.76M-$-227.94M
Capital expenditure-$-33.84M-$-11.07M-$-22.29M-$-20.43M-$-37.57M
Free cash flow-$-336.24M-$-364.05M-$-384.11M-$-313.18M-$-265.51M
Total assets$913.2M$910.4M$780.4M$664M$777.3M
Total debt$48.4M$58.3M$75.9M$85.5M$71.5M
Net debt-$-114.63M-$-57.43M-$-39.03M-$-146.28M-$-6.7M
Total equity$698.6M$710.4M$584.6M$499.6M$621.7M
Cash and short-term investments$297M$323.8M$279.9M$471.9M$504.4M
Income statement
20252024202320222021
Revenue$263.5M$164.1M$1.19M$0.00$0.00
Cost of revenue$7.29M$124M$10.8M$0.00$0.00
Gross profit$256.2M$40.1M-$-9.57M$0.00$0.00
Research and development expenses$300.3M$282.3M$344.1M$294.8M$259M
Selling, general and administrative expenses$152.3M$153M$106.9M$104.1M$83.7M
Other expenses$207M$0.00$0.00$0.00$0.00
Operating expenses$659.6M$435.4M$451M$398.9M$342.7M
Cost and expenses$666.9M$559.4M$461.8M$398.9M$342.7M
Interest income$0.00$20.3M$13M$2.98M$450K
Interest expense$0.00$0.00$0.00$2.98M$0.00
Depreciation and amortization$35.9M$43.6M$33.1M$21.1M$14M
Ebitda-$-357.11M-$-331.4M-$-414.39M-$-371.77M-$-328.27M
Operating income-$-403.36M-$-395.28M-$-460.56M-$-398.88M-$-342.7M
Total other income/expenses, net$10.3M$20.3M$13M$2.98M$450K
Income before tax-$-393.05M-$-375M-$-447.52M-$-395.89M-$-342.25M
Income tax expense-$-2.07M-$-2.83M-$-3.48M$0.00$0.00
Net income-$-390.98M-$-372.18M-$-444.04M-$-395.89M-$-342.25M
Weighted average shares outstanding$357.4M$289.9M$235.1M$159.3M$153.4M
Weighted average diluted shares outstanding$357.4M$289.9M$235.1M$159.3M$153.4M
Balance sheet
20252024202320222021
Cash and short-term investments$297M$323.8M$279.9M$471.9M$504.4M
Net receivables$82.5M$69.3M$150K$0.00$0.00
Inventory$51.7M$51.5M$10.4M$0.00$0.00
Total current assets$442.7M$457M$307.9M$479.1M$508M
Property, plant and equipment, net$177M$164.3M$176.5M$178.3M$169.9M
Goodwill and intangible assets$279.3M$282.4M$229.3M$0.00$0.00
Long-term investments$0.00$0.00$66.4M$0.00$91.6M
Total non-current assets$470.5M$453.4M$472.5M$184.9M$269.4M
Total assets$913.2M$910.4M$780.4M$664M$777.3M
Accounts payable$22.2M$27.5M$33.1M$26.6M$27.4M
Short-term debt$4.04M$12.9M$7.78M$12.6M$5.06M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$138.4M$122.3M$110.3M$91.5M$89.2M
Long-term debt$44.4M$45.4M$68.1M$72.9M$66.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$76.2M$77.7M$85.4M$72.9M$66.5M
Capital lease obligations$44.4M$57.3M$74.9M$84.5M$70.5M
Total liabilities$214.6M$200M$195.7M$164.3M$155.7M
Common stock$20K$10K$10K$10K$10K
Retained earnings-$-2.78B-$-2.38B-$-2.01B-$-1.57B-$-1.17B
Accumulated other comprehensive income (loss)$16.4M-$-1.05M$2.53M-$-900K-$-600K
Total equity$698.6M$710.4M$584.6M$499.6M$621.7M
Total investments$133.9M$208.1M$231.4M$240.1M$517.8M
Total debt$48.4M$58.3M$75.9M$85.5M$71.5M
Net debt-$-114.63M-$-57.43M-$-39.03M-$-146.28M-$-6.7M
Cash flow statement
20252024202320222021
Net income-$-390.98M-$-372.18M-$-444.04M-$-395.89M-$-342.25M
Depreciation and amortization$34.5M$43.6M$33.1M$21.1M$14M
Stock-based compensation$61.6M$109.6M$62.6M$84M$69.8M
Change in working capital-$-24.27M-$-122.56M-$-6.52M-$-2.89M$24.6M
Accounts receivable-$-13.11M-$-69.19M-$-150K$0.00$0.00
Inventory-$-14.21M-$-39.92M-$-10.12M$0.00$0.00
Accounts payable-$-6.66M-$-7.84M$4.83M$5.88M$6.98M
Net cash provided by operating activities-$-302.41M-$-352.98M-$-361.82M-$-292.76M-$-227.94M
Investments in property, plant and equipment-$-33.84M-$-11.07M-$-22.29M-$-20.43M-$-37.57M
Acquisitions, net$0.00-$-52.57M-$-212.63M-$-276.88M-$-37.71M
Net cash used for investing activities$47.5M-$-96.41M-$-155.24M$256.5M$130K
Common stock issued$306.3M$397.3M$463.3M$189.5M$203.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$300.8M$390.7M$463M$190.2M$239.3M
Net change in cash$47.4M-$-59.27M-$-56.84M$153.9M$11.5M
Cash at end of period$169.1M$122.1M$181.3M$238.2M$84.3M
Operating cash flow-$-302.41M-$-352.98M-$-361.82M-$-292.76M-$-227.94M
Capital expenditure-$-33.84M-$-11.07M-$-22.29M-$-20.43M-$-37.57M
Free cash flow-$-336.24M-$-364.05M-$-384.11M-$-313.18M-$-265.51M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Iovance Biotherapeutics, Inc.

        Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.

        CEO
        Frederick G. Vogt
        Employees
        975
        Beta
        0.69

        Explore

        Frequently asked questions

        What is the intrinsic value of Iovance Biotherapeutics, Inc. (IOVA)?

        Iovance Biotherapeutics, Inc. (IOVA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IOVA undervalued?

        IOVA trades at a price of $6.90 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.